Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Bausch Health Companies Inc.NYSE: BHC
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $54M rose 17.4% year over year, ahead of the +12.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Stock-based compensation amounted to 2.1% of revenue in FY2025, up 0.5 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.4% holds above the trailing-twelve-month pace of +12.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 216M USD
- Year-over-year change
- +44.0%
- 4-year CAGR
- +14.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 216M | +44.0% |
| FY2024 | 2024-12-31 | 150M | +13.6% |
| FY2023 | 2023-12-31 | 132M | +4.8% |
| FY2022 | 2022-12-31 | 126M | -1.6% |
| FY2021 | 2021-12-31 | 128M | — |
Stock-Based Compensation vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 stock-based compensation of $149M is the largest of the 11 companies compared; the peer median is $19.59M.
- Its year-over-year change of +12.9% is the 4th highest of 11, against a peer median of -7.1%.
- Stock-based compensation amounts to 1.4% of revenue for BHC, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $149M | +12.9% | +19.7% | 1.4% | |
| LTM Jun 2026 | $33.83M | +8.0% | +9.8% | 2.5% | |
| LTM Mar 2026 | $29.06M | -7.1% | +37.5% | 3.1% | |
| LTM Mar 2026 | $25.19M | +26.9% | +46.3% | 4.2% | |
| LTM Jun 2026 | $25.03M | +73.0% | +248.9% | — | |
| LTM Jun 2026 | $21.2M | -17.8% | — | 0.5% | |
| LTM Jun 2025 | $17.99M | -47.3% | -20.6% | 3.0% | |
| LTM Mar 2026 | $16.07M | +356.7% | +19.0% | 2.9% | |
| LTM Mar 2026 | $16M | -57.9% | -17.6% | 0.4% | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $5.93M | -7.1% | — | 0.3% |
| Peer median (excluding BHC) | $19.59M | -7.1% | +14.4% | 2.9% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (937M) | (212M) | (611M) | (72M) | 120M |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| Deferred Income Tax | (225M) | (176M) | 51M | 66M | 80M |
| Stock-Based Compensation | 128M | 126M | 132M | 150M | 216M |
| Change in Working Capital | (128M) | (396M) | (582M) | 7M | (222.83M) |
| Accounts Receivables | (229M) | (57M) | (195M) | (216M) | (136.35M) |
| Inventory | (16M) | (198M) | (322M) | (267M) | (12.21M) |
| Accounts Payables | 121M | (75M) | 158M | 357M | (77.33M) |
| Other Working Capital | (4M) | (66M) | (223M) | 133M | 3.05M |
| Other Non-Cash Items | 1.04B | (1.46B) | 778M | 179M | (1.17M) |
| Operating Cash Flow | 1.43B | (728M) | 1.03B | 1.6B | 1.4B |
| Capital Expenditures | (283M) | (268M) | (272M) | (337M) | (397M) |
| Acquisitions (Net) | 0 | (45M) | (1.89B) | 0 | 0 |
| Purchases of Investments | (19M) | (17M) | (27M) | (12M) | (11M) |
| Sales of Investments | 15M | 22M | 26M | 14M | 8M |
| Other Investing Activities | 682M | (45M) | (39M) | (119M) | (195M) |
| Investing Cash Flow | 409M | (303M) | (2.15B) | (454M) | (595M) |
| Debt Repayment | (1.34B) | (1.01B) | 1.58B | (799M) | (648.15M) |
| Common Stock Issued | 0 | 675M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (26M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (173M) | (139M) | (106M) | (43M) | (93.85M) |
| Financing Cash Flow | (1.51B) | (474M) | 1.48B | (868M) | (742M) |
| Effect of Forex Changes | (19M) | (23M) | 9M | (36M) | 61M |
| Net Change in Cash | 303M | (1.53B) | 371M | 239M | 124M |
| Free Cash Flow | 1.14B | (996M) | 760M | 1.26B | 1B |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.